Literature DB >> 1955776

Local complement activation in inflammatory bowel disease.

T S Halstensen1, P Brandtzaeg.   

Abstract

To trace sites for local complement activation in inflammatory bowel disease, an indirect two-colour immunofluorescence method was applied on prewashed and directly ethanol-fixed mucosal specimens from patients with ulcerative colitis, Crohn's colitis, or terminal ileitis. Monoclonal antibodies to the IgG subclasses and to neoepitopes of activated complement C3b and the terminal complement complex (TCC) were used in combination with rabbit antiserum to immunoglobulins and various complement components. Deposits of activated C3b were found on the luminal face of the surface epithelium in the most affected ulcerative colitis specimens from 91% of 23 studied patients, together with cytolytic TCC in 81%. Furthermore, there was a selective deposition of the immunoglobulin G subclass 1 (IgG1) within the epithelial immune complexes in 63% of 11 studied patients. These results suggested that IgG1 autoantibodies to brush-border antigen(s) induce a complement-mediated attack on the epithelium in ulcerative colitis. The epithelial complement deposition seen in Crohn's disease tended to be more granular and was observed in 5 of 10 patients with colitis and in 4 of 10 with ileitis. No co-localization of IgG was observed, suggesting that complement activation had been induced by the alternative pathway. Type III immune reaction may, in addition, take place in both diseases since there was evidence of continuous vascular complement activation in submucosal blood vessels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955776     DOI: 10.1007/bf02919746

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  26 in total

Review 1.  Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes.

Authors:  P Brandtzaeg; T S Halstensen; K Kett; P Krajci; D Kvale; T O Rognum; H Scott; L M Sollid
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

2.  Various keratin antibodies produce immunohistochemical staining of human myocardium and myometrium.

Authors:  H S Huitfeldt; P Brandtzaeg
Journal:  Histochemistry       Date:  1985

3.  Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction.

Authors:  A J Wakefield; A M Sawyerr; A P Dhillon; R M Pittilo; P M Rowles; A A Lewis; R E Pounder
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

Review 4.  Anaphylatoxins: C3a and C5a.

Authors:  T E Hugli; H J Müller-Eberhard
Journal:  Adv Immunol       Date:  1978       Impact factor: 3.543

5.  Evidence of cytotoxicity in ulcerative colitis from immunofluorescent staining of the rectal mucosa.

Authors:  J Ballard; M Shiner
Journal:  Lancet       Date:  1974-05-25       Impact factor: 79.321

Review 6.  The immunologic basis of inflammatory bowel disease.

Authors:  W Strober; S P James
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

7.  Intestinal fine structure in Crohn's disease. Lysosomal inclusions in epithelial cells and macrophages.

Authors:  J Thyberg; W Graf; P Klingenström
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

8.  Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon.

Authors:  T S Halstensen; T E Mollnes; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1989-03       Impact factor: 23.059

9.  Enhanced local production of complement components in the small intestines of patients with Crohn's disease.

Authors:  O Ahrenstedt; L Knutson; B Nilsson; K Nilsson-Ekdahl; B Odlind; R Hällgren
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

10.  Evaluation of tissue preparation methods and paired immunofluorescence staining for immunocytochemistry of lymphomas.

Authors:  P Brandtzaeg; T O Rognum
Journal:  Histochem J       Date:  1983-07
View more
  7 in total

1.  Factors affecting antigen uptake by human intestinal epithelial cell lines.

Authors:  A L So; G Small; K Sperber; K Becker; E Oei; M Tyorkin; L Mayer
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

2.  Regulation of the alternative pathway of complement modulates injury and immunity in a chronic model of dextran sulphate sodium-induced colitis.

Authors:  M Elvington; J Schepp-Berglind; S Tomlinson
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

3.  The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10.

Authors:  U Jain; T M Woodruff; A W Stadnyk
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

4.  Accumulation of immunoglobulin-containing cells in the gut mucosa and presence of faecal immunoglobulin in severe combined immunodeficient (scid) mice with T cell-induced inflammatory bowel disease (IBD).

Authors:  S Bregenholt; J Brimnes; J Reimann; M H Claesson
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

5.  A novel protocol allowing oral delivery of a protein complement inhibitor that subsequently targets to inflamed colon mucosa and ameliorates murine colitis.

Authors:  M Elvington; P Blichmann; F Qiao; M Scheiber; C Wadsworth; I Luzinov; J Lucero; A Vertegel; S Tomlinson
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

6.  Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis.

Authors:  Jennifer Schepp-Berglind; Carl Atkinson; Michelle Elvington; Fei Qiao; Peter Mannon; Stephen Tomlinson
Journal:  J Immunol       Date:  2012-05-07       Impact factor: 5.422

7.  A Phase-Variable Surface Layer from the Gut Symbiont Bacteroides thetaiotaomicron.

Authors:  Mao Taketani; Mohamed S Donia; Amy N Jacobson; John D Lambris; Michael A Fischbach
Journal:  MBio       Date:  2015-09-29       Impact factor: 7.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.